Mazdutide vs Tirzepatide: Dosage, Efficacy & Mechanism
A side-by-side, peer-reviewed comparison of Mazdutide and Tirzepatide — mechanism, typical research dose and titration, clinical-trial efficacy, administration, and reconstitution. For research and educational purposes only.
| Attribute | Mazdutide | Tirzepatide |
|---|---|---|
| Drug class | Weight Loss | Weight Loss |
| Mechanism of action | Mazdutide is a 29-amino-acid peptide based on the glucagon/GLP-1 hybrid structure of oxyntomodulin, modified with a C18 fatty-acid linker that provides albumin binding and supports weekly subcutaneous dosing. The peptide has balanced agonism at both the… | Tirzepatide is engineered around a modified GIP backbone with C20 fatty-diacid acylation that binds albumin to produce a terminal half-life of roughly 5 days, allowing fixed-dose weekly subcutaneous injection . The molecule is a balanced agonist at the GIP… |
| Typical research dose | 2.5–6 mg once weekly with gradual titration. | 2.5–15 mg once weekly (gradual 4‑week titration steps). |
| Headline trial efficacy | Systolic blood pressure reductions of 5–8 mmHg and waist-circumference reductions of 8–10 cm were observed at the 6 mg dose in Phase 3, paralleling the central adiposity reductions seen with comparable molecules. | SUMMIT (Packer et al., NEJM 2024) showed tirzepatide reduced the composite of cardiovascular death and worsening heart failure by 38% in patients with obesity-related HFpEF, suggesting cardiovascular benefit beyond glycemia and weight. |
| Administration | Refer to guidelines | Refer to guidelines |
| Vial sizes | 5 mg, 10 mg | 5 mg, 10 mg, 15 mg, 30 mg |
| Storage | Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); discard after 28 days.[7][9] | Lyophilized frozen; reconstituted refrigerated for up to 28 days. |
Frequently Asked Questions
What is the difference between Mazdutide and Tirzepatide?expand_more
Mazdutide (weight loss) and Tirzepatide (weight loss) differ in receptor target and mechanism. Mazdutide is a 29-amino-acid peptide based on the glucagon/GLP-1 hybrid structure of oxyntomodulin, modified with a C18 fatty-acid linker that provides albumin binding and supports weekly subcutaneous dosing. The peptide has balanced agonism at both the… By contrast, tirzepatide: Tirzepatide is engineered around a modified GIP backbone with C20 fatty-diacid acylation that binds albumin to produce a terminal half-life of roughly 5 days, allowing fixed-dose weekly subcutaneous injection . The molecule is a balanced agonist at the GIP…
How do the typical research doses of Mazdutide and Tirzepatide compare?expand_more
Mazdutide is typically dosed at 2.5–6 mg once weekly with gradual titration., while Tirzepatide is typically dosed at 2.5–15 mg once weekly (gradual 4‑week titration steps).. See each protocol for the full titration schedule.